This upstream thesis really requires common outcomes in the three disease trials, per your post. A failure here with PDD compared to successes in Rett's and AD would be, literally, inexplicable in terms of prior research.
Given conventional wisdom that "there is no silver bullet," how long will it take for investors to react to good news on this trial, after preliminary good indications with Rett's and Alzheimer's? That will be an interesting test of cognitive dissonance versus greed.
Thanks for your usual thoughtful and very clear explanation.